NAFLD is considered to cover a spectrum of disease activity. This spectrum begins as fatty accumulation in the liver (hepatic steatosis). A liver can remain fatty without disturbing liver function, but by varying mechanisms and possible insults to the liver may also progress to become non-alcoholic steatohepatitis (NASH), a state in which steatosis is combined with inflammation and fibrosisNAFLD can also be caused by some medications
•Antiviral drugs (nucleoside analogues)
•Aspirin rarely as part of Reye's syndrome in children
The prevalence of NAFLD is 20-30%. About 2-3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and hepatocarcinoma. As a rule, the prevalence of NAFLD is higher in males and increases with increasing age, and it is influenced by the diagnostic method and the characteristics of the population, especially lifestyle habits.NAFLD typically shows up as an unexpected abnormality in liver function tests, usually the alanine aminotransferase (ALT) test, in people who otherwise feel well. The elevation of this test generally is minor and in younger patients, does not indicate a serious liver condition. However, if the cause of NAFLD, such as obesity or diabetes, is not treated, the condition may progress.